	US 12,258,418 B2
	Claudin18.2 binding moieties and uses thereof
Liusong Yin, Nanjing (CN); Tielin Zhou, Singapore (SG); Zhuo Fang, Nanjing (CN); Yong Liu, Nanjing (CN); Qiuchuan Zhuang, Nanjing (CN); Bo Wu, Nanjing (CN); Xiaohu Fan, Nanjing (CN); Qingshan Zhang, Nanjing (CN); Dan Zhao, Nanjing (CN); and Jie Mao, Nanjing (CN)
Assigned to Nanjing GenScript Biotech Co., Ltd., Nanjing (CN); and Nanjing Legend Biotech Co., Ltd, Nanjing (CN)
Appl. No. 17/419,203
Filed by Nanjing GenScript Biotech Co., Ltd., Nanjing (CN); and Nanjing Legend Biotech Co., Ltd., Nanjing (CN)
PCT Filed Dec. 27, 2019, PCT No. PCT/CN2019/129017 § 371(c)(1), (2) Date Jun. 28, 2021, PCT Pub. No. WO2020/135674, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. PCT/CN2018/125052 (WO), filed on Dec. 28, 2018; and application No. PCT/CN2019/095827 (WO), filed on Jul. 12, 2019.
Prior Publication US 2022/0073643 A1, Mar. 10, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/3046 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

20 Claims

1. A binding moiety that specifically binds to Claudin18.2, comprising:

(1) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 77, 102, and 124, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 141, 148, and 161, respectively;

(2) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 78, 103, and 125, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 143, and 162, respectively;

(3) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 79, 104, and 126, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 149, and 163, respectively;

(4) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 78, 105, and 127, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143, and 164, respectively; or

(5) VH CDR1, VH CDR2, and VH CDR3, comprising the amino acid sequences of SEQ ID NOs: 209, 103 and 125, respectively; and VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 136, 143, and 162, respectively.